Lyphomed/NNP Inc./NNP ,/, Rosemont/NNP ,/, Ill./NNP ,/, and/CC Medco/NNP Research/NNP Inc./NNP ,/, Los/NNP Angeles/NNP ,/, said/VBD 0/-NONE- the/DT Food/NNP and/CC Drug/NNP Administration/NNP granted/VBD full/JJ marketing/NN approval/NN for/IN a/DT new/JJ drug/NN for/IN the/DT treatment/NN of/IN a/DT condition/NN in/IN which/WDT the/DT heart/NN beats/VBZ between/IN 150/CD and/CC 200/CD beats/NNS a/DT minute/NN *T*-1/-NONE- ./.
The/DT condition/NN ,/, known/VBN */-NONE- as/IN paroxysmal/JJ supraventricular/JJ tachycardia/NN ,/, leads/VBZ to/TO dizziness/NN and/CC fainting/NN ./.
The/DT typical/JJ healthy/JJ heart/NN beats/VBZ 70/CD times/NNS a/DT minute/NN ./.
The/DT drug/NN ,/, called/VBN */-NONE- adenocard/NN ,/, returns/VBZ the/DT heart/NN to/TO a/DT normal/JJ rhythm/NN within/IN seconds/NNS ,/, according/VBG to/TO Lyphomed/NNP ./.
Medco/NNP Research/NNP developed/VBD the/DT drug/NN and/CC licensed/VBD it/PRP to/TO Lyphomed/NNP for/IN sale/NN in/IN the/DT U.S./NNP and/CC Canada/NNP ./.

